Fierce Biotech
Merck hands over $20M in IBD drug target deal with Flagship’s Quotient
Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering’s Quotient Therapeutics $20 million upfront for access to the biotech’s somatic genomics platform.